This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/5/2026
Good afternoon and welcome to ARS Farmers Third Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the company's prepared remarks, we will open the line for questions. Please be advised that today's conference is being recorded. I will now like to turn the call over to Monique Allaire, IR Representative for the company. Please go ahead.
Good afternoon, and thank you all for joining us. With me on the call today are President and CEO Don Casale, Chief Commercial Officer Meg Smith, and our Chief Financial Officer Kathy Scott. Earlier today, we issued a press release outlining ARS Pharma's commercial highlights and financial results for the third quarter of 2026. That press release can be found in the Investors and Media section of the company's website at ars-pharma.com. Before we begin, please note that today's remarks may contain forward-looking statements and actual results may differ materially. Please refer to our press release and SEC filings for further risk disclosures. With that, I'll turn the call over to Don.
Thank you, Monique, and good afternoon, everyone. In August, I outlined a new strategic direction for ARS and laid out three corporate priorities to build a durable, profitable business. The first is disrupting the legacy epinephrine market with NEFI, delivering steady market share gains through targeted provider commercial execution. The second is reaching past low break even by year end 2027, based on greater financial discipline that will continue through 2027. The third is expanding our epinephrine delivery platform beyond anaphylaxis, and unlocking value with a potential first on-demand treatment of breakthrough flares and chronic spontaneous urticaria, or CSU. I'm very proud of our progress last quarter and the team's execution against each of these priorities. In the third quarter, NEFI continued to capture market share, delivering $33.4 million in U.S. net product revenue. Total U.S. market share surpassed 5%, up from 4% in the third quarter of 2025. This was driven by a 42% year-over-year increase in NEFI end-user demand. We recorded more than 19,000 unique prescribers in the third quarter, up 49% year over year, for a total of nearly 45,000 prescribers since launch. The impact of our commercial execution is even more evident when you look at market share and field targeted accounts, which represent about 44% of the total market opportunity. Field targeted share increased from 6% in Q3 last year to 9% in Q3 this year. compared with 2% in non-targeted accounts. So where our field team engages, NEFI wins. On our second priority, we have implemented strict financial discipline that we will maintain going forward. Operating expenses in Q3 were in line with the guidance we selected and set last year, reflecting our ongoing commitment to reducing SG&A spend. SG&A expenses in Q3 were down by more than 40% compared to the prior two quarters of this year. Based on our revised expense plan, we reaffirmed that we are on track to achieve cash flow breakeven by year-end 2027. Third, on our pipeline, our Phase IIb trial with ARS2 is progressing well, and we expect to report interim data in the first quarter of 2027. An estimated 2 million Americans live with CSU, A debilitating inflammatory condition marked by episodes of severe itch and hives. While biologics have a meaningfully improved disease control for many patients, breakthrough flares are common. About 60% of adults remain symptomatic despite taking four times the standard dose of antihistamines, and a third to more than half of patients on approved biologics are not well controlled. There are no FDA-approved therapies indicated to stop a breakthrough flare in progress today. When a severe flare occurs, physicians typically turn to oral corticosteroids, which have side effects that limit their long-term use. This is the opportunity we see for ARS2, rapid, on-demand relief of breakthrough flares rather than another chronic maintenance therapy. Results from our completed Phase II trial show ARS2 improved both itch and high scores, beginning as early as five minutes after dosing. In our exploratory phase 2b trial, we're evaluating 0.5 milligram and one milligram doses of ARS2 to identify the minimum effective dose. The trial is progressing and we're on track to report interim data in the first quarter of 2027. With the interim data, we also plan to share highlights from an ongoing market assessment, including claims analysis and pair research. The interim findings, along with the full data expected later in 2027, will guide the plans and design of our Phase III registration program. ARS2 could add meaningful platform value as potential first FDA-approved, on-demand treatment for breakthrough flares in CSU, including in patients on biologics. Importantly, this is an indication we could commercialize efficiently and effectively using the same sales force we have for NEFI today. If we execute on each of these objectives, I believe we can create a meaningful value for our stakeholders over both the near and long term. To get there, we have brought in multiple senior leaders with proven track records. We recently appointed Dr. Randall Kaye as Chief Medical Officer. Randall is an allergist and an immunologist with more than 30 years in medicine. We also recently appointed John Fleaver as Chief Legal Officer, bringing expertise across business operations and many more. And in August, Meg Smith joined us as Chief Commercial Officer. Meg is a commercial expert with a record of winning in prevention-type markets. She knows how to lead teams that drive behavior change. With that, let me turn the call over to Meg for a commercial update.
You're reading a preview of the SPRY Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing